Forum Financial Management LP Increases Holdings in Sanofi (NASDAQ:SNY)

Forum Financial Management LP raised its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 76.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,827 shares of the company's stock after purchasing an additional 28,879 shares during the period. Forum Financial Management LP's holdings in Sanofi were worth $3,223,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. State Street Corp lifted its stake in shares of Sanofi by 0.5% in the 3rd quarter. State Street Corp now owns 56,734 shares of the company's stock valued at $3,270,000 after acquiring an additional 264 shares during the last quarter. Barclays PLC boosted its position in Sanofi by 107.5% during the 3rd quarter. Barclays PLC now owns 639,772 shares of the company's stock worth $36,869,000 after buying an additional 331,445 shares during the period. Geode Capital Management LLC grew its stake in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after purchasing an additional 16,780 shares during the last quarter. World Investment Advisors LLC raised its position in shares of Sanofi by 1,020.5% during the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock worth $2,791,000 after acquiring an additional 44,108 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Sanofi during the third quarter worth $219,000. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

NASDAQ:SNY traded up $0.96 during mid-day trading on Wednesday, reaching $52.81. The stock had a trading volume of 1,746,567 shares, compared to its average volume of 2,358,827. Sanofi has a one year low of $45.80 and a one year high of $60.12. The stock has a market capitalization of $133.41 billion, a P/E ratio of 21.21, a P/E/G ratio of 1.01 and a beta of 0.57. The firm has a 50 day moving average price of $54.61 and a two-hundred day moving average price of $52.11. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's payout ratio is presently 64.26%.

Analyst Ratings Changes

A number of research firms have issued reports on SNY. BNP Paribas assumed coverage on Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.